250 related articles for article (PubMed ID: 29790694)
1. Advances in antibody therapeutics targeting small-cell lung cancer.
Lu H; Jiang Z
Adv Clin Exp Med; 2018 Sep; 27(9):1317-1323. PubMed ID: 29790694
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
[TBL] [Abstract][Full Text] [Related]
3. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
4. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
[TBL] [Abstract][Full Text] [Related]
5. Development of antibody therapeutics for small cell lung cancer.
Zhan J; Han Q; Wang K
Expert Opin Investig Drugs; 2013 Feb; 22(2):235-44. PubMed ID: 23176362
[TBL] [Abstract][Full Text] [Related]
6. Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.
Cao H; Dong W; Shen H; Xu J; Zhu L; Liu Q; Du J
PLoS One; 2015; 10(8):e0135844. PubMed ID: 26287334
[TBL] [Abstract][Full Text] [Related]
7. Ganitumab for the treatment of small-cell lung cancer.
Martínez P; Sales Fidalgo PA; Felip E
Expert Opin Investig Drugs; 2014 Oct; 23(10):1423-32. PubMed ID: 25189625
[TBL] [Abstract][Full Text] [Related]
8. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
10. A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
Lebron MB; Brennan L; Damoci CB; Prewett MC; O'Mahony M; Duignan IJ; Credille KM; DeLigio JT; Starodubtseva M; Amatulli M; Zhang Y; Schwartz KD; Burtrum D; Balderes P; Persaud K; Surguladze D; Loizos N; Paz K; Kotanides H
Cancer Biol Ther; 2014 Sep; 15(9):1208-18. PubMed ID: 24921944
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
[TBL] [Abstract][Full Text] [Related]
12. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
14. Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer.
Kinehara Y; Minami T; Kijima T; Hoshino S; Morimura O; Otsuka T; Hayama Y; Fukushima K; Takeuchi Y; Higashiguchi M; Miyake K; Hirata H; Nagatomo I; Inoue K; Takeda Y; Kida H; Kumanogoh A
Lung Cancer; 2015 Mar; 87(3):321-5. PubMed ID: 25601188
[TBL] [Abstract][Full Text] [Related]
15. Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
Armstrong SA; Liu SV
Curr Oncol Rep; 2020 Feb; 22(2):20. PubMed ID: 32034529
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
17. Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
Stinchcombe TE
Oncologist; 2017 Dec; 22(12):1510-1517. PubMed ID: 28778960
[TBL] [Abstract][Full Text] [Related]
18. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
19. CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.
Lindner DJ; Wildey G; Parker Y; Dowlati A; Stark GR; De S
Br J Cancer; 2021 Mar; 124(5):893-895. PubMed ID: 33257843
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
